New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 14, 2014
10:14 EDTBANC, PPC, SIGI, LOW, TKC, NSH, INDB, TESO, TEVA, NSOn The Fly: Analyst Upgrade Summary
Banc of California (BANC) upgraded to Buy from Neutral at Sterne Agee... Independent Bank (INDB) upgraded to Outperform from Market Perform at Keefe Bruyette... Lowe's (LOW) upgraded to Outperform from Perform at Oppenheimer... NuStar Energy (NS) upgraded to Buy from Neutral at Goldman... NuStar GP Holdings (NSH) upgraded to Neutral from Sell at Goldman... Selective Insurance (SIGI) upgraded to Outperform from Market Perform at Keefe Bruyette... Teva (TEVA) upgraded to Neutral from Underweight at JPMorgan... Turkcell (TKC) upgraded to Buy from Neutral at UBS... Pilgrim's Pride (PPC) upgraded to Overweight from Equal Weight at Stephens... Tesco (TESO) upgraded to Overweight from Equalweight at Capital One.
News For BANC;INDB;LOW;NS;NSH;SIGI;TEVA;TKC;PPC;TESO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
January 21, 2015
10:01 EDTLOWOn the Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Ashford Hospitality (AHT) upgraded to Outperform from Neutral at Credit Suisse... BAE Systems (BAESY) upgraded to Buy from Neutral at Goldman... Bazaarvoice (BV) upgraded to Outperform from Market Perform at Cowen... Becton Dickinson (BDX) upgraded to Outperform at Cowen... CVS Health (CVS) upgraded to Buy from Neutral at Goldman... Camden Property (CPT) upgraded to Outperform from Neutral at Credit Suisse... ConocoPhillips (COP) upgraded to Buy from Neutral at BofA/Merrill... Cornerstone OnDemand (CSOD) upgraded to Buy from Neutral at DA Davidson... Cree (CREE) upgraded to Overweight at Stephens... DDR Corp. (DDR) upgraded to Outperform from Neutral at Credit Suisse... EastGroup Properties (EGP) upgraded to Outperform from Neutral at Credit Suisse... Energy Transfer Partners (ETP) upgraded to Outperform from Neutral at Credit Suisse... Esperion (ESPR) upgraded at BofA/Merrill... Exxon Mobil (XOM) upgraded to Outperform from Market Perform at Wells Fargo... FXCM (FXCM) upgraded to Market Perform from Underperform at Keefe Bruyette... Fair Isaac (FICO) upgraded to Overweight from Equal Weight at Barclays... Golar LNG (GLNG) upgraded to Buy from Hold at Nordea... Gran Tierra (GTE) upgraded to Buy at Canaccord... Host Hotels (HST) upgraded to Outperform from Neutral at Credit Suisse... J.M. Smucker (SJM) upgraded to Overweight from Neutral at JPMorgan... Kilroy Realty (KRC) upgraded to Neutral from Underperform at Credit Suisse... Level 3 (LVLT) upgraded to Outperform from Market Perform at Wells Fargo... Lowe's (LOW) upgraded to Overweight from Equal Weight at Morgan Stanley... Michael Kors (KORS) upgraded to Outperform at Cowen... Netflix (NFLX) upgraded at Nomura... Regions Financial (RF) upgraded to Buy from Neutral at Guggenheim... Ruckus Wireless (RKUS) upgraded to Outperform from Market Perform at Northland... Santander Mexico (BSMX) upgraded to Neutral from Underperform at Credit Suisse... Scorpio Tankers (STNG) upgraded to Buy at Canaccord... Sprouts Farmers Markets (SFM) upgraded to Buy from Neutral at BofA/Merrill... Strategic Hotels (BEE) upgraded to Outperform from Neutral at Credit Suisse... The Medicines Co. (MDCO) upgraded to Outperform from Market Perform at Leerink... Whole Foods (WFM) upgraded at Sterne Agee... Wolseley (WOSYY) upgraded to Neutral from Underperform at Exane BNP Paribas.
09:31 EDTLOWLowe's says to hire approximately 30,000 seasonal employees
Subscribe for More Information
08:38 EDTTEVAMomenta announces Supreme Court decision to remand generic Copaxone back to CAFC
Subscribe for More Information
06:52 EDTLOWLowe's upgraded to Overweight from Equal Weight at Morgan Stanley
Morgan Stanley upgraded Lowe's based on increased confidence in execution, accelerating category growth from the ongoing housing recovery and lower gas prices which the firm believes will drive earnings and EBIT margins. Price target raised to $80.
January 20, 2015
14:37 EDTTEVATeva generic competition to Copaxone pushed out by ruling, says BMO Capital
Subscribe for More Information
12:56 EDTTEVAMylan says continues to believe '808 patent is 'invalid'
Subscribe for More Information
11:29 EDTTEVATeva says Supreme Court reverses circuit court judgment on Copaxone 20 mg/mL
Teva Pharmaceutical announced the U.S. Supreme Court’s decision in Teva Pharmaceuticals USA, Inc. et al. Petitioners v. Sandoz Inc. et al. that reversed the Federal Circuit Court’s judgment of invalidity of Teva’s ‘808 patent for COPAXONE 20 mg/mL. The Supreme Court remanded the case to the Federal Circuit for further review in light of the applicable standard the Supreme Court laid out for appellate review of claim construction. A ruling last year by the U.S. Court of Appeals for the Federal Circuit upheld four Teva patents that expired in May 2014, while invalidating the ‘808 patent that is set to expire on September 1, 2015. “We are encouraged by the U.S. Supreme Court’s Decision and look forward to the Federal Circuit’s review. We will continue to explore all available avenues to protect our intellectual property for COPAXONE 20mg/mL,” said Erez Vigodman, President and CEO of Teva. “There is currently no FDA-approved follow-on version of Teva’s COPAXONE. We are encouraged by the FDA’s willingness to date to have dialogue regarding the complexities of COPAXONE 20 mg/mL and the potential limitations and other unknowns of purported follow-on versions,” added Rob Koremans, MD, President and CEO of Global Specialty Medicines at Teva.
10:45 EDTPPCOptions with increasing implied volatility
Subscribe for More Information
10:45 EDTTEVATeva spikes, retraces, after win in Copaxone patent case
Subscribe for More Information
10:40 EDTTEVAMomenta Pharma sinks after Supreme Court rules on Copaxone
Subscribe for More Information
10:35 EDTTEVATeva rises after patent ruling upheld by Supreme Court
The Supreme Court upheld a lower court ruling related to generic versions of Teva's Copaxone drug. In the ruling, the court wrote that "When reviewing a district court’s resolution of subsidiary factual matters made in the course of its construction of a patent claim, the Federal Circuit must apply a “clear error,” not a de novo, standard of review." Teva shares are up 1.5% to $58.58 in early trading after the ruling. Reference Link
January 16, 2015
10:27 EDTPPCOptions with increasing implied volatility
Subscribe for More Information
10:01 EDTNSOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:30 EDTNSNuStar Energy downgraded to Underweight from Equal Weight at Morgan Stanley
Subscribe for More Information
January 15, 2015
12:26 EDTPPCOn The Fly: Midday Wrap
Subscribe for More Information
09:15 EDTPPCOn The Fly: Pre-market Movers
Subscribe for More Information
January 14, 2015
19:01 EDTPPCPilgrim's Pride declares $5.77 per share special dividend
Pilgrim's Pride Corporation announced that as part of its strategy of improving its capital structure and generating shareholder value, its board has approved the declaration of a special cash dividend of $5.77 per share. The total amount of the special dividend payment will be approximately $1.5B based on the current number of shares outstanding. The special cash dividend is payable on February 17 to stockholders of record on January 30.
January 13, 2015
10:00 EDTBANCOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
07:18 EDTBANCBanc of California downgraded at BofA/Merrill
As previously reported, BofA/Merrill downgraded Banc of California to Neutral from Buy. The firm downgraded shares based on relative valuation. Price target is $12.50.
06:02 EDTBANCBanc of California downgraded to Neutral from Buy at BofA/Merrill
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use